CSL (CSLLY) Forward PE Ratio : 31.17 (As of Apr. 25, 2024)

View and export this data going back to 2008. Start your Free Trial

What is CSL Forward PE Ratio?

CSL's Forward PE Ratio for today is 31.17.

CSL's PE Ratio without NRI for today is 35.43.

CSL's PE Ratio for today is 35.43.

CSL Forward PE Ratio Historical Data

The historical data trend for CSL's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Forward PE Ratio Chart

CSL Annual Data

Trend

2015-12

2016-12

2017-12

2018-12

2019-12

2020-12

2021-12

2022-12

2023-12

2024-04

Forward PE Ratio

26.53

26.67

31.06

31.35

40.32

42.19

45.05

41.84

27.55

30.03

CSL Semi-Annual Data
	2015-12	2016-03	2016-06	2016-09	2016-12	2017-03	2017-06	2017-09	2017-12	2018-03	2018-06	2018-09	2018-12	2019-03	2019-06	2019-09	2019-12	2020-03	2020-06	2020-09	2020-12	2021-03	2021-06	2021-09	2021-12	2022-03	2022-06	2022-09	2022-12	2023-03	2023-06	2023-09	2023-12	2024-03
Forward PE Ratio	26.53	21.46	22.22	27.40	26.67	24.75	26.88	30.67	31.06	29.15	33.22	33.78	31.35	29.67	32.68	35.09	40.32	32.05	39.84	43.67	42.19	40.82	43.86	46.51	45.05	38.17	40.49	35.46	41.84	31.35	33.44	27.70	27.55	32.15

Competitive Comparison of CSL's Forward PE Ratio

For the Biotechnology subindustry, CSL's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSL's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where CSL's Forward PE Ratio falls into.

CSL Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

CSL (OTCPK:CSLLY) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

CSL Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of CSL's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL (CSLLY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

CMXHF:USA CSJ:Germany CSL:Australia

Address

655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website

https://www.csl.com

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.